Partners

Mutabilis is actively pursuing collaborations with non-commercial organizations and pharmaceutical partners for scientific expertise and funding support. We currently have alliances with or receive funding support from the following:

 

CARB-X for EBL-1463 program

As announced in February 2021, CARB-X is awarding Mutabilis up to US$6.4 million to develop EBL-1463,  a new drug to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria. Under the award agreement, Mutabilis will be eligible for an additional $5.8 million in further funding if certain project milestones are met, subject to available funds.

 

Novo Holdings REPAIR Impact fund for 2G-Dabocin program

In January 2020,  Novo Holdings REPAIR Impact fund announced a EUR 7 (USD 8) million investment in Mutabilis. This investment will allow the company to accelerate this 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.

 

Roche for 2G-Dabocin program

In February 2022,  Mutabilis announced collaboration with Roche to develop a new class of antibiotics to treat infections caused by WHO critical priority pathogens. Under the agreement, Mutabilis will lead all activities until entry into GLP tox, whereupon Roche would take over all further research activities and development with the aim to commercialize a new antibiotic to treat multidrug-resistant infections.